Latest Share Chat

IN BRIEF: Angle responds to additional information request from US FDA

Fri, 04th Jun 2021 18:02

Angle PLC - liquid biopsy company - Confirms that it has completed the work required to answer questions raised by US Food & Drug Administration in its additional information request and submitted the response. Angle says it continues to anticipate a regulatory decision from US regulator during the second half of 2021.

Current stock price: 128.00 pence

Year-to-date change: more than doubled from 47.75p on December 31

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Related Shares

More News

21 Jun 2024 10:52

IN BRIEF: Angle says open offer raises proceeds of GBP500,000

Angle PLC - Guildford, England-based liquid biopsy company - Receives valid applications for a total of 3.6 million open offer shares from qualifying ...

5 Jun 2024 16:32

EARNINGS AND TRADING: STV sees advertising upturn; Angle loss narrows

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately repor...

5 Jun 2024 10:08

Angle unveils plans to raise more than £10m

(Sharecast News) - Liquid biopsy specialist Angle is to raise more than £10m to support future growth, the UK company announced on Wednesday.

16 May 2024 20:09

TRADING UPDATES: Bens Creek considers administration; Nexxen inks deal

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

16 May 2024 11:46

Angle reports promising results from Parsortix study

(Sharecast News) - Angle, the AIM-listed liquid biopsy company which specialises in circulating tumour cell (CTC) solutions, has announced the results...